---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-043726"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:56:53.961631+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology Q2 2021 net loss $12.7M; cash $264M, IK-412 IND delayed by supply

## Summary
- Cash and cash equivalents $264.0M as of June 30, 2021; expected to fund operations through 2023.
- Net loss $12.7M in Q2 2021 vs $5.0M in Q2 2020; R&D expense $11.4M vs $6.3M.
- IK-930 IND submission on track for end of 2021; preclinical data at EORTC-NCI-AACR conference.
- IK-175 monotherapy expansion cohort enrolling additional bladder cancer patients; clinical data planned in 2022.
- IK-412 IND submission delayed due to shortage of a component required for COVID-19 vaccines.

## SEC filing metadata
- accession: 0001564590-21-043726
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000156459021043726/0001564590-21-043726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000156459021043726/ikna-8k_20210812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-043726
- JSON: https://secwatch.observer/filing/0001564590-21-043726.json
- Plain text: https://secwatch.observer/filing/0001564590-21-043726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.